Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

ONVO opened at $0.61 on Monday. The stock has a market capitalization of $10.59 million, a PE ratio of -0.71 and a beta of 0.54. The stock’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.45. Organovo has a 52-week low of $0.32 and a 52-week high of $1.83.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Research analysts forecast that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.